The Priority Review

Tag

Parkinson disease

1 story

  1. Clinical trials

    NOPARK trial reports nicotinamide riboside does not improve clinical outcomes in Parkinson disease

    The authors reported that among 393 participants, the total MDS-UPDRS score increased by 2.45 points with nicotinamide riboside and decreased by 0.27 points with placebo, yielding an adjusted mean difference of 2.72 points favoring placebo. Non-motor symptom burden worsened more with nicotinamide riboside, with an adjusted mean difference of 4.22 points.